The Back Room: Freaking Out or Winding Down?
This week: an art-market Omicron primer, downtown New York dealers on the move, a coveted Magritte appears under Bonhams’s hammer, and more.
Stay updated with breaking news from Jonathan Casella. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This week: an art-market Omicron primer, downtown New York dealers on the move, a coveted Magritte appears under Bonhams’s hammer, and more.
We scoured the aisles of Art Basel Miami Beach, NADA, Untitled, and more to bring you a list of artists who are going places.
Health by Jane Hansen Premium Content Subscriber only It is one of the most expensive drugs to ever hit the market, but at $3.5 million per one-off dose, it can mean the difference between life and death for a baby born with spinal muscular atrophy (SMA). Zolgensma, a gene therapy, is approved by the Therapeutic Good Administration (TGA) but is currently facing a Pharmaceutical Benefits Advisory Board (PBAC) decision on whether to list it for subsidy on the Pharmaceutical Benefits Scheme. One in 35 people carry the gene mutation for SMA. SMA leads to par...